NCT06235645Recruiting
dEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound
Source: ClinicalTrials.gov · Last updated 30 Apr 2026
Brief summary (registry, in English)
Rheumatoid arthritis is an autoimmune disease that can affect various organs, including the lungs, and lead to rheumatoid arthritis-interstitial lung disease (RA-ILD). RA-ILD is responsible for increased mortality in rheumatoid arthristis (RA) patients. The prevalence of RA-ILD varies according to the screening tool used. The current gold standard is chest CT, but this is an expensive, time-consuming and irradiating examination, and recommendations on when and how often it should be performed are not clearly established. Lung ultrasound (LUS) is an emerging tool for the detection of lung parenchymal damage, particularly in systemic scleroderma and idiopathic pulmonary fibrosis (IPF). LUS is a non-irradiating, non-expensive examination that can be performed rapidly. The aim of our study is to evaluate LUS as a screening tool for RA-ILD, in patients with risk factors for developing RA-ILD.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 280 (estimated)
- First submitted
- 23 Jan 2024
- Start date
- 18 Nov 2024
- Primary completion date
- Nov 2026
- Lead sponsor
- University Hospital, Tours
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT06235645
What you commit to
- Study type: Observational
- Planned participants: 280
- From 18 Nov 2024 to the primary completion date, Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Thoracic irradiation
- Thoracic transplant patients
- Parenchymal infection current or less than one month old prior to LUS examination
Other illness
- Diagnosis of congenital lung disease
- Diagnosis of another autoimmune pathology associated with RA (overlap syndrome) linked to the development of ILD (interstitial lung disease) (systemic sclerosis, myositis, dermatomyositis, mixed connectivitis, systemic lupus erythematosus or other ANCA vasculitis, with the exception of secondary Gougerot-Sjögren's syndromes).
- Current or operated lung cancer
- Pathologies responsible for pleural thickening (silicosis, asbestosis, known pleural plaque, pleural sequelae of tuberculosis)
Other
- Previous invasive thoracic procedures
- Pregnant or breast-feeding women
- Patient under legal protection (guardianship, curatorship or safeguard of justice)
- Patient who has objected to data processing
- Liquid or gaseous pleural effusion
Who the study is looking for
- Adult patient (age \> 18 years) followed at CHU of Tours
- Diagnosis of rheumatoid arthritis validated according to ACR 2010 criteria, EULAR classification, regardless of time since diagnosis
- Patient who has had or will have a thoracic CT scan and PFT performed as part of routine care in the 6 months preceding or following inclusion
- Patient with at least two risk factors for developing RA-ILD among :
- Male sex or
- Active or former smoker assessed at 20 pack-year or
- Age \> 60 years or
- Levels of RF≥3N (rheumatoid factor) and/or anti-CCP≥3N (antibodies against cyclic citrullinated peptides) at diagnosis or at any time during the course of the disease or
- High RA activity score (DAS28\>3.2)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| university hospital, Tours Coordinator of this site? Confirm its status | Tours | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.